Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Individualized Functional Connectivity Targeting in Accelerated Intelligent Neuromodulation Therapy (AINT) for Depression

NCT05680727 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT05680727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05680727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Individualized Functional Connectivity Targeting in Accelerated Intelligent Neuromodulation Therapy (AINT) for Depression
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 15, 2023
Completion date
February 17, 2026
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depression, depressive disorder, major, mental disorder, mood disorders, psychiatric disorder